Navigation Links
New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Date:9/19/2007

HONOLULU, Sept. 19 /PRNewswire-FirstCall/ -- Results from a Phase III clinical trial evaluating the efficacy and safety of risedronate 150 mg once monthly for the treatment of postmenopausal osteoporosis were presented at the American Society for Bone and Mineral Research (ASBMR) 29th Annual Meeting. In the non-inferiority study comparing risedronate 150 mg once monthly to risedronate 5 mg daily [Actonel(R) (risedronate sodium tablets)] increases in bone mineral density (BMD) were similar for patients taking either the monthly or daily dosing regimens.

In the study, BMD was measured at the lumbar spine, total hip, femoral neck, and femoral trochanter. There were no statistically significant differences in BMD increases between the risedronate 150 mg once monthly and the 5 mg daily dose groups at 12 months. In the study, the tolerability and safety profiles were also similar for the monthly and daily dosing regimens of risedronate.

"Risedronate is already approved to reduce the risk of both spinal and nonspinal fractures," said Michael McClung, M.D., Founding Director of the Oregon Osteoporosis Center in Portland, Oregon. "For patients who prefer less frequent dosing, risedronate 150 mg, if approved, would provide the convenience of a once monthly dosing option."

About the Study

The MERIT-OP (Monthly Evaluation of Risedronate Trial in Osteoporosis) study is a 2-year, randomized, double-blind, active-control (5 mg daily risedronate) clinical trial which evaluated 1,292 postmenopausal women (94% Caucasian) between 50 and 88 years old, mean age 64.9, from 47 clinical centers in 13 countries. The participants had osteoporosis, defined as a lumbar spine (LS) BMD T-score less than -2.5 or a LS BMD T-score less than - 2.0 and at least one prevalent vertebral fracture. Patients were randomized to dosing regimens of either risedronate 150 mg monthly or risedronate 5 mg daily and received daily supplements of calcium (1,000 mg) and vitamin D (400
'/>"/>

SOURCE The Alliance for Better Bone Health
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... , April 27, 2015 Harwood Feffer ... the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" ... the board has breached its fiduciary duties to shareholders. ... a press release announcing results from its first Phase ... press release disclosed that in the trial, Rhopressa failed ...
(Date:4/27/2015)... Research and Markets ( ... "Endoscopy Global Market - Forecast to 2020" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , ,The global endoscopy market ... 2019 growing at around 7.0% CAGR from 2014 ... growth are aging population, increase in cancer, diabetes, ...
(Date:4/27/2015)... , April 27, 2015 Vermillion, ... on gynecologic disease, announced today it will ... the market close on Monday, May 11, ... and webcast at 4:30pm Eastern.Conference Call & ... Eastern/1:30pm Pacific Domestic: , 888-556-4997International: , 719-457-2628Conference ...
Breaking Medicine Technology:Harwood Feffer LLP Announces Investigation of Aerie Pharmaceuticals, Inc. 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 2Endoscopy Global Market - Forecast to 2020: Market is expected to reach approximately $43 billion with Johnson and Johnson, Olympus and Covidien Dominating 3
(Date:4/27/2015)... On April 16, 2015, Harper’s Bazaar Magazine, in ... Marks ,” interviewed a UK dermatologist on the causes and ... are a type of scar that reportedly affects nearly 90% ... of the elsastin and collagen in the dermis, the dense ... mark removal with the Coolbeam protocol is one of our ...
(Date:4/27/2015)... 2015 Beckman Coulter is sponsoring a ... study the evolution of neural circuitry and swimming behavior ... the mechanisms by which analogous forms of swimming behavior, ... evolved independently in certain sea slug clades. The webinar ... April 30, 2015 at 8:00am PT. , Sea slugs ...
(Date:4/27/2015)... Humble, TX (PRWEB) April 27, 2015 Sitting ... legs to ache and feel tired, and for those whose ... such as receptionists and taxi cab drivers, or to be ... teachers and hairdressers, the discomfort can be more severe and ... tired, achy leg syndrome. Dr. Madaiah Revana of Northeast Houston ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 FMC ... will exhibit its wide range of market leading ingredients ... May 7 in Geneva, Switzerland. Vitafoods Europe 2015 expects ... 100 countries showcasing the latest research in such areas ... nutrition. , FMC Health and Nutrition’s booth will ...
(Date:4/27/2015)... (PRWEB) April 27, 2015 Telematics Berlin ... tier 1&2 suppliers, associations, CE players and the government ... has opened to the car. This year’s panel on ... DG-Move at the European Commission, is an opportunity to ... and define a European Automotive Security Standard for years ...
Breaking Medicine News(10 mins):Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 2Health News:Beckman Coulter Genomics Presents Using Next-Gen Sequencing to Study the Evolution of Neural Circuitry 3Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 2Health News:Northeast Houston Vein Center Offers Tips on How to Treat Achy Legs 3Health News:FMC Health and Nutrition to Feature Epax® Brand Omega-3 Ingredients at Vitafoods Europe 2015 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 2Health News:Telematics Berlin: European Commission discuss a pan European Automotive Security Strategy 3
... 25 Smart Balance Inc.,(Nasdaq: SMBL ) will ... on Wednesday, May 21, 2008, at the Teaneck Marriott ... 07666. Stockholders of record,at the close of business on ... all matters that properly come before the meeting., ...
... passed the Genetic Information Nondiscrimination Act (GINA) on April 24, ... which passed the House April 25, 2007 by a vote ... measure again quickly before sending it to President Bush to ... wait, Americans can now be confident that their genetic information ...
... A Johns Hopkins University biologist, in research with implications ... has determined that the eye uses light to reset ... ability to see. , The findings suggest that patients ... can be linked to lack of exposure to daylight ...
... InfoLogix, Inc.,(Nasdaq: IFLG ), a leading technology ... commercial industries, will release its,financial results for the ... 30th, 2008. Following the press release, President and ... Jay Roberts will,host a conference call with the ...
... had less blood loss, shorter hospital stays, study finds ... laparoscopic surgery to remove pancreatic tumors or cysts leads ... study finds. , In laparoscopic surgery, doctors make ... progress with fiber optics and video cameras. This less ...
... (OTC Bulletin,Board: NTRZ), a world leader in stabilized ... that it has entered into,definitive agreements to sell ... of $20,000,000. The offering is made,pursuant to the ... by,NutraCea with the Securities and Exchange Commission (the ...
Cached Medicine News:Health News:Genetic Information Nondiscrimination Act clears Senate 2Health News:Different processes govern sight, light detection 2Health News:InfoLogix to Report First Quarter Results on April 30, 2008 2Health News:Laparoscopic Surgery on Pancreas Has Fewer Complications 2Health News:NutraCea Announces $20 Million Securities Offering 2Health News:NutraCea Announces $20 Million Securities Offering 3
Inquire...
Inquire...
Inquire...
The modular, high-end stereomicroscope; meets even the most critical demands in research and quality control provides high-contrast images with excellent depth of field and color fidelity...
Medicine Products: